EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impaired fibrinolysis in patients with atrial fibrillation and elevated circulating lipopolysaccharide

Marcin Sadowski, Michał Ząbczyk, Anetta Undas

Journal of Thrombosis and Thrombolysis · 2024

DOI: 10.1007/s11239-024-02980-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2024. Verfasst von Marcin Sadowski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Collegium Medicum, Jan Kochanowski University, Kielce, Poland. Hauptthemen laut MEDLINE: Atrial Fibrillation, Lipopolysaccharides, Fibrinolysis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wydział Lekarski, Uniwersytet Jagielloński Collegium Medicum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is unknown whether elevated gut-derived serum lipopolysaccharide (LPS) can affect thrombin generation, fibrinolysis, and fibrin clot properties in atrial fibrillation (AF). We aimed to evaluate associations of circulating LPS with prothrombotic markers in AF patients. A total of 157 (women, 57.3%) ambulatory anticoagulant-naïve AF patients aged from 42 to 86 years were recruited. Clinical data together with serum LPS, inflammation, endothelial injury, coagulation and fibrinolysis markers, including fibrin clot permeability (K s ) and clot lysis time (CLT), were analyzed. A median LPS concentration was 73.0 (58.0-100.0) pg/mL and it showed association with CLT ( r = 0.31, p < 0.001) and plasminogen activator inhibitor-1 (PAI-1, r = 0.57, p < 0.001), but not other fibrinolysis proteins, thrombin generation, inflammatory markers, or K s . There were weak associations of LPS with von Willebrand factor (vWF, r = 0.2, p = 0.013), cardiac troponin I ( r = 0.16, p = 0.045), and growth differentiation factor-15 ( r = 0.27, p < 0.001). No associations of LPS and CHA 2 DS 2 -VASc or other clinical variables were observed. Multivariable regression adjusted for potential confounders showed that serum LPS ≥ 100 pg/mL was an independent predictor of prolonged CLT. This study is the first to demonstrate antifibrinolytic effects of elevated LPS in AF patients largely driven by enhanced PAI-1 release.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationLipopolysaccharidesFibrinolysisHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overBiomarkersPlasminogen Activator Inhibitor 1Fibrin Clot Lysis Time

Stichwörter der Autor:innen

Atrial fibrillationClot propertiesFibrinolysisGut microbiotaLipopolysaccharide

Substanzen

LipopolysaccharidesBiomarkersPlasminogen Activator Inhibitor 1

Autor:innen und Institutionen

  • Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
  • Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
  • Krakow Centre for Medical Research and Technologies, John Paul II Hospital, Krakow, Poland.
  • Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. mmundas@cyf-kr.edu.pl.
  • Krakow Centre for Medical Research and Technologies, John Paul II Hospital, Krakow, Poland. mmundas@cyf-kr.edu.pl.

Förderung

  • Wydział Lekarski, Uniwersytet Jagielloński Collegium Medicum

Zitieren

APA

Sadowski, M., Ząbczyk, M., & Undas, A. (2024). Impaired fibrinolysis in patients with atrial fibrillation and elevated circulating lipopolysaccharide. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-024-02980-5

Vancouver

Sadowski M, Ząbczyk M, Undas A. Impaired fibrinolysis in patients with atrial fibrillation and elevated circulating lipopolysaccharide. Journal of Thrombosis and Thrombolysis. 2024. doi:10.1007/s11239-024-02980-5

BibTeX
@article{Sadowski2024,
  author = {Sadowski, Marcin and Ząbczyk, Michał and Undas, Anetta},
  title = {Impaired fibrinolysis in patients with atrial fibrillation and elevated circulating lipopolysaccharide},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2024},
  doi = {10.1007/s11239-024-02980-5}
}
Kostenlos starten →